Table 5.
Laboratory parameters, somatic anomalies and clinical features differentiating between 33 women with Turner syndrome treated or not treated with growth hormone in childhood; GH therapy duration <3 years or ≥3 years. V – absolute values and (%) – percentages. Superscript P-value statistically significant compared to TS women not treated with growth hormone in childhood.
| Parameters [normal ranges] |
GH < 3 (n = 18) |
GH ≥ 3 (n = 15) |
GH < 3 vs GH ≥ 3 P - value |
|---|---|---|---|
| Height (cm) | 148.5 ± 6.650.0387 | 148 ± 6.70.0105 | 0.8649 |
| BMI (kg/m2) | 21.8 ± 40.0139 | 21.6 ± 3.30.0064 | 0.9136 |
| Time of GH exposition (y) | 1.5 ± 0.6 | 5.27 ± 1.5 | 0.0000 |
| FSH (IU/L) [2.8–11.3] | 49.9 ± 230.0076 | 50.5 ± 320.0595 | 0.7255 |
| E2 (pmol/L) [66–884] | 123 ± 135 | 188 ± 187 | 0.7448 |
| Cholesterol (mmol/L) [3.9–5] | 4.57 ± 0.93 | 4.63 ± 0.84 | 0.8654 |
| HDL (mmol/L) [>1] | 1.28 ± 0.25 | 1.46 ± 0.47 | 0.1605 |
| LDL (mmol/L) [<3] | 3 ± 0.94 | 3 ± 0.58 | 0.9962 |
| TG (g/L) [0.4–1.7] | 0.96 ± 0.5 | 0.82 ± 0.30.0498 | 0.3838 |
| Creatinine (µmol/L [60–130] | 59 ± 12 | 65.5 ± 110.0356 | 0.0707 |
| Red blood cells (1012/L) [4.2–5] | 4.57 ± 0.26 | 4.77 ± 0.28 | 0.0424 |
| Thrombocytes (109/L) [150–300] | 208.5 ± 520.0049 | 252.8 ± 41 | 0.0117 |
| V (%) | V (%) | ||
| Retrognathism | 14 77.8 | 12 80 | 0.8776 |
| Fingernail anomalies | 13 72.20.05 | 9 50 | 0.1905 |
| Ingrowing nails | 7 38.90.0474 | 5 33.3 | 0.7391 |
| Blood pressure ≥ 140/90 mmHg | 1 5.60.0345 | 3 20 | 0.2073 |
| Urinary system malformations | 5 27.8 | 5 33.30.06 | 0.7321 |
| HRT | 12 66.7 | 8 53.3 | 0.4328 |